Meet Judith Lebambo*. She is one of a brave group of male and female volunteers prepared to enter great risks by testing the efficacy of the first HIV vaccine designed to stop a strain of HIV which is dominant in southern Africa, reports City Press.
Lebambo, from Soshanguve, northern Pretoria, is one of 5 400 people who are HIV negative and between the ages of 18 and 35, who will be participating in the HVTN702 HIV vaccine trial.
The trial, which began on October 26, aims to determine if an HIV vaccine regimen is safe, tolerable and effective in the long run in preventing HIV infection among South African adults.
Read more on City Press’s website.
*Judith Lebambo is not her real name.